In the EURTAC study, in which erlotinib was compared with platinum-doublet chemotherapy as first-line treatment for patients with EGFR-mutant NSCLC, erlotinib demonstrated a significant improvement in the overall response rate (ORR) and median progression free survival (PFS).2 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.